Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCT-01-097 in advanced solid tumors
NCT04761601Phase 1Terminated
- Sponsor
- 1200 Pharma
- Start
- Mar 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of UCT-01-097 in solid tumor (advanced stage) (3 arms), sponsored by 1200 Pharma. Primary endpoints: Incidence and severity of adverse events and serious adverse events up to 2 years, Maximum Tolerated Dose at 28 Days and 1 more. Started Mar 2021; status: terminated.
02
Drugs
UCT-01-097
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04761601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04761601.